A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects

Willem Hettema; Christopher Wynne; Benjamin Lang; Mario Altendorfer; Niklas Czeloth; Ragna Lohmann; Sandeep Athalye; Dorothee Schliephake

doi:10.1080/13543784.2017.1347635

A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects

Expert Opinion on Investigational Drugs ◽

10.1080/13543784.2017.1347635 ◽

2017 ◽

Vol 26 (8) ◽

pp. 889-896 ◽

Cited By ~ 9

Author(s):

Willem Hettema ◽

Christopher Wynne ◽

Benjamin Lang ◽

Mario Altendorfer ◽

Niklas Czeloth ◽

...

Keyword(s):

Phase I ◽

Healthy Subjects ◽

Phase I Trial ◽

Single Blind

Download Full-text

A Randomized, Single-Blind, Phase I Trial (INVICTAN®-1) Assessing the Pharmacokinetic Bioequivalence and Safety of BI 695502, a Bevacizumab Biosimilar Candidate, in Healthy Subjects

10.26226/morressier.57d6b2b8d462b8028d88ea33 ◽

2016 ◽

Author(s):

Mario Altendorfer

Keyword(s):

Phase I ◽

Healthy Subjects ◽

Phase I Trial ◽

Single Blind

Download Full-text

BCX7353, a Potent Inhibitor of Plasma Kallikrein, Shows Sustained Maximal Enzyme Inhibition When Dosed Orally Once Daily: Results from a Phase I Trial in Healthy Subjects

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2015.12.1243 ◽

2016 ◽

Vol 137 (2) ◽

pp. AB401 ◽

Cited By ~ 3

Author(s):

Melanie Cornpropst ◽

Sylvia Dobo ◽

Jo Collier ◽

Angela Rose ◽

Ramanda Wilson ◽

...

Keyword(s):

Phase I ◽

Enzyme Inhibition ◽

Healthy Subjects ◽

Phase I Trial ◽

Potent Inhibitor ◽

Plasma Kallikrein ◽

Once Daily

Download Full-text

Safety, Tolerability (S&T) and Pharmacokinetics (PK) of Single and Repeat Inhaled Doses of Phosphoinositide-3-Kinase Delta Inhibitor (PI3Kδ) GSK2269557, Delivered via the ELLIPTATM Device to Healthy Subjects in a Phase I Trial, Including Charcoal Block

10.1183/1393003.congress-2017.pa520 ◽

2017 ◽

Author(s):

Robert Wilson ◽

Emily Jarvis ◽

Mickael Montembault ◽

Nicole Hamblin ◽

Edith M. Hessel ◽

...

Keyword(s):

Phase I ◽

Healthy Subjects ◽

Phase I Trial ◽

Phosphoinositide 3 Kinase

Download Full-text

Study on Pharmacokinetic Interactions Between HS-10234 and Emtricitabine in Healthy Subjects: An Open-Label, Two-Sequence, Self-Controlled Phase I Trial

Infectious Diseases and Therapy ◽

10.1007/s40121-021-00555-y ◽

2021 ◽

Author(s):

Yeping Luo ◽

Wenjing Chen ◽

Guoping Yang ◽

Chan Zou ◽

Jie Huang ◽

...

Keyword(s):

Phase I ◽

Healthy Subjects ◽

Phase I Trial ◽

Open Label ◽

Pharmacokinetic Interactions

Download Full-text

Effect of gender and age on the relative bioavailability of doravirine: results of a Phase I trial in healthy subjects

Antiviral Therapy ◽

10.3851/imp3142 ◽

2017 ◽

Vol 22 (4) ◽

pp. 337-344 ◽

Cited By ~ 16

Author(s):

Martin O Behm ◽

Ka L Yee ◽

Li Fan ◽

Paul Fackler

Keyword(s):

Phase I ◽

Healthy Subjects ◽

Phase I Trial ◽

Relative Bioavailability ◽

Gender And Age

Download Full-text

A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects

CNS Drugs ◽

10.1007/s40263-020-00738-0 ◽

2020 ◽

Vol 34 (8) ◽

pp. 853-865 ◽

Cited By ~ 1

Author(s):

Michael J. Fossler ◽

Virginia Schmith ◽

Stephen A. Greene ◽

Lauren Lohmer ◽

Michael S. Kramer ◽

...

Keyword(s):

Phase I ◽

G Protein ◽

Healthy Subjects ◽

Receptor Agonist ◽

Dose Study ◽

Delta Receptor ◽

Single Blind ◽

Single Ascending Dose Study

Download Full-text

Safety and Tolerability of Conserved Region Vaccines Vectored by Plasmid DNA, Simian Adenovirus and Modified Vaccinia Virus Ankara Administered to Human Immunodeficiency Virus Type 1-Uninfected Adults in a Randomized, Single-Blind Phase I Trial

PLoS ONE ◽

10.1371/journal.pone.0101591 ◽

2014 ◽

Vol 9 (7) ◽

pp. e101591 ◽

Cited By ~ 49

Author(s):

Emma-Jo Hayton ◽

Annie Rose ◽

Umar Ibrahimsa ◽

Mariarosaria Del Sorbo ◽

Stefania Capone ◽

...

Keyword(s):

Human Immunodeficiency Virus ◽

Phase I ◽

Vaccinia Virus ◽

Plasmid Dna ◽

Phase I Trial ◽

Modified Vaccinia Virus Ankara ◽

Immunodeficiency Virus ◽

Simian Adenovirus ◽

Single Blind

Download Full-text

604: A Phase I Trial of Vaccination of Personalized Peptides for HLA-A2/A24 Positive Patients with Hormone-Refractory Prostate Cancer

The Journal of Urology ◽

10.1016/s0022-5347(18)30844-9 ◽

2007 ◽

Vol 177 (4S) ◽

pp. 202-202

Author(s):

Hirotsugu Uemura ◽

Motoyoshi Tanaka ◽

Shigeya Uejima ◽

Takafumi Minami ◽

Kiyohide Fujimoto ◽

...

Keyword(s):

Prostate Cancer ◽

Phase I ◽

Phase I Trial ◽

Hormone Refractory Prostate Cancer ◽

Hormone Refractory

Download Full-text

Phase I Trial and Pharmacokinetics Study of the Farnesyltransferase Inhibitor Tipifarnib in Children With Refractory Solid Tumors or Neurofibromatosis Type I and Plexiform Neurofibromas

Yearbook of Oncology ◽

10.1016/s1040-1741(08)70478-0 ◽

2007 ◽

Vol 2007 ◽

pp. 292-293

Author(s):

R.J. Arceci

Keyword(s):

Phase I ◽

Solid Tumors ◽

Phase I Trial ◽

Neurofibromatosis Type ◽

Type I ◽

Neurofibromatosis Type I ◽

Farnesyltransferase Inhibitor ◽

Plexiform Neurofibromas ◽

Pharmacokinetics Study

Download Full-text

The PACOVAR-trial: A multicenter phase I trial of pazopanib (GW786034) and metronomic cyclophosphamide in patients with recurrent platinum-resistant ovarian cancer

Geburtshilfe und Frauenheilkunde ◽

10.1055/s-0036-1592664 ◽

2016 ◽

Vol 76 (10) ◽

Author(s):

C Mayer ◽

M Schmidt ◽

EM Grischke ◽

G Gebauer ◽

HC Fricke ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Phase I Trial ◽

Multicenter Phase ◽

Platinum Resistant ◽

Metronomic Cyclophosphamide

Download Full-text